Lakefront Biotherapeutics (LKFT) Operating Expenses (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Operating Expenses for 12 consecutive years, with -$36.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 81.11% year-over-year to -$36.3 million; the TTM figure through Mar 2026 stood at -$355.7 million (up 6.94% YoY), while the FY2025 annual figure was -$534.8 million, down 49.16% from the prior year.
• Operating Expenses advanced to -$36.3 million in Q1 2026 per LKFT's latest filing, from -$125.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $619.9 million in Q4 2022 and bottomed at -$204.6 million in Q4 2023.
• Historically, Operating Expenses has averaged -$43.4 million across 5 years, with a median of -$77.8 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 95.77% — and 2025, when it tumbled 1345.7%.
• Lakefront Biotherapeutics' Operating Expenses stood at $619.9 million in 2022, then tumbled by 133.01% to -$204.6 million in 2023, then soared by 95.77% to -$8.7 million in 2024, then sank by 1345.7% to -$125.1 million in 2025, then surged by 71.0% to -$36.3 million in 2026.
• Business Quant data shows LKFT's Operating Expenses at -$36.3 million in Q1 2026, -$125.1 million in Q4 2025, and -$86.4 million in Q3 2025.